Charming Medical Limited MCTA
- Market cap
- $497.3M
- P/E
- —
Follow MCTA
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 4.30 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 31.70 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | 49 |
Employees
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | 0 |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
Charming Medical Limited peers in Medical Care Facilities
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SRTA Strata Critical Medical, Inc. | $476.8M | 10.5× | Compare |
| CYH Community Health Systems, Inc. | $406.1M | 1.6× | Compare |
| STLN Starling Oncology, Inc. | $650.9M | 0.0× | Compare |
| AUNA Auna S.A. | $311.0M | 73.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| INNV InnovAge Holding Corp. | $1.2B | 0.0× | Compare |
| USPH U.S. Physical Therapy, Inc. | $1.3B | 499× | Compare |
| AGL Agilon Health, Inc. | $1.3B | 0.0× | Compare |
| AMN AMN Healthcare Services Inc | $1.3B | 12.8× | Compare |
Charming Medical Limited (MCTA) Latest News
26 Nov
Nasdaq has halted trading of Charming Medical Limited (MCTA) due to concerns regarding the company's compliance with listing standards. The suspension follows a series of regulatory issues that have raised questions about the company's financial practices and governance. Investors are advised to monitor the situation closely as the company works to address these concerns and restore trading. Regulatory issues and trading halts can significantly impact investor sentiment and the company's operational trajectory.
30 Oct
CHARMING MEDICL (MCTA) is highlighted as a promising investment opportunity in the US market for October 2025, showcasing its innovative healthcare solutions and potential for growth. The company is positioned to capitalize on emerging trends in the medical sector, with a focus on expanding its product offerings and enhancing patient care. Analysts suggest that MCTA's strategic initiatives and market positioning could lead to significant returns for investors in the coming years. MCTA's strategic initiatives and market positioning are expected to significantly alter its trajectory and investor sentiment.
28 Oct
Charming Medical Limited has announced the full exercise of the representative's over-allotment option related to its recent public offering. This move allows underwriters to purchase additional shares, enhancing the total capital raised during the offering. The decision reflects strong demand for the company's shares and aims to bolster its financial position. The full exercise of the over-allotment option indicates strong market interest, which may positively influence financial performance.
22 Oct
Charming Medical Limited has successfully closed its initial public offering (IPO), raising significant capital to support its growth and expansion plans. The IPO attracted considerable investor interest, reflecting confidence in the company's business model and future prospects. The funds raised will be utilized for research and development, enhancing product offerings, and expanding market reach. This milestone marks a pivotal moment for Charming Medical as it transitions into a publicly traded entity. The successful IPO is expected to provide substantial capital for growth initiatives, significantly impacting the company's future trajectory.
21 Oct
Charming Medical Limited has announced the pricing of its initial public offering (IPO) at $10 per share, aiming to raise approximately $10 million. The shares are set to be listed on Nasdaq under the ticker symbol MCTA. The IPO is expected to enhance the company's capital structure and support its growth initiatives in the medical sector. The IPO represents a significant strategic move that could enhance capital for growth and impact investor sentiment.